Key Highlights
- Group Revenue was A$1.18 million for the September 2026 quarter, up 86% on the prior corresponding quarter but down 48% on the June quarter.
- The U.S. Phase 2b trial contract was amended to expand from 30 to 45 investigational sites.
- Total contract value rose to US$0.95 million, a 33% increase on the original US$0.72 million.
- Closing cash was A$0.50 million at 30 September 2026, after share purchase plan and Placement proceeds of about A$1.10 million.
CONNEQT Health Limited (ASX:CQT) released its September 2026 quarter update on 30 October 2026, and an announcement on 9 November 2026 confirming an expansion of its U.S. Phase 2b clinical trial contract. The vascular health company reported quarterly group revenue, a drop from the June quarter and a cash balance of A$0.50 million, followed by the contract expansion.
Quarterly Revenue
Group revenue was A$1.18 million, up 86% on the September 2025 quarter of A$0.63 million, but down 48% on the June 2026 quarter of A$2.28 million.
Phase 2b Contract Expansion
On 9 November 2026, Subsidiary ATCOR Medical executed an amendment to expand its Phase 2b trial contract with a privately owned U.S. biopharmaceutical company, from 30 to 45 investigational sites. The amendment adds a second study visit to the protocol.
The incremental value is US$0.24 million, lifting the total contract value to US$0.95 million from US$0.72 million. The company will Supply 15 additional SphygmoCor XCEL systems and 30 Oscar 2 ABPM systems for about seven months. A 30% initiation fee is payable on execution, with the balance invoiced monthly.
Cash and Funding
Closing cash was A$0.50 million at 30 September 2026. The company said it received about A$1.10 million of cash proceeds from its share purchase plan and Tranche 2 of the June 2026 placement during the period.
Sector Context and Risks to Watch
Clinical trial contracts for device-based endpoints can be extended by sponsors, but they can also be reduced or delayed, and revenue is recognised over the trial. The contract's value depends on the number of sites that are activated.
The main risks are the cash balance relative to the quarterly revenue pattern, the activation of the additional sites and the timing of revenue recognition. Future updates will show the trial progress.
Final Word
CONNEQT's contract expansion increases the value of its U.S. trial, but the quarter's revenue fell from June and cash of A$0.50 million is limited. The next reports are expected to show site activation and whether revenue recovers.






Please wait processing your request...